体外细胞类型供应商bit.bio获得5000万美元C轮融资，加速人类细胞编程技术规模化应用-动脉网

bit.bio secures $50 million Series C to scale human cell programming technology

D-Pharm 等信源发布 2026-01-21 10:16



可切换为仅中文







bit.bio, Cambridge-based pioneer in next-generation human cell programming, has successfully closed a $50 million Series C funding round led by M&G

剑桥下一代人类细胞编程领域的先驱 bit.bio 已成功完成由 M&G 领投的 5000 万美元 C 轮融资。

investments

投资

. This injection of patient capital from a major UK investor represents a significant endorsement of the company's mission to transform the future of drug development and innovation within the United Kingdom.

这家英国主要投资者注入的耐心资本，代表了对公司使命的重大认可，即变革英国的药物研发和创新未来。

This capital infusion allows bit.bio to move toward several key strategic milestones, including accelerating the development and delivery of our core product pipeline while scaling our operational footprint to meet global demand. The company is expanding into the multi-billion dollar toxicology market and generating the high-fidelity datasets necessary to train advanced AI models for .

这笔资金的注入使 bit.bio 能够朝着几个关键的战略里程碑迈进，包括加速核心产品线的开发和交付，同时扩大我们的运营规模以满足全球需求。公司正在进军价值数十亿美元的毒理学市场，并生成用于训练先进 AI 模型所需的高保真数据集。

drug discovery

药物发现

。

Central to this effort is bit.bio's ioCells™ technology, which facilitates a global shift toward New Approach Methodologies (NAMs), in particular, advanced cell-based models that improve the predictiveness of new medicines while reducing industry reliance on animal testing.

这项工作的核心是 bit.bio 的 ioCells™ 技术，它促进了全球向新方法学（NAMs）的转变，特别是先进的基于细胞的模型，这些模型提高了新药的预测性，同时减少了行业对动物测试的依赖。

Alongside this funding, bit.bio is pleased to welcome Lord David Prior to our leadership team as an independent director and Board Chair. Lord Prior’s twenty-year tenure in UK Life Sciences and health policy will be vital as we navigate our growth from a private entity toward public markets.

伴随着这笔资金，bit.bio 很高兴欢迎大卫·普赖尔勋爵加入我们的领导团队，担任独立董事兼董事会主席。普赖尔勋爵在英国生命科学和卫生政策领域拥有二十年的经验，这将为我们从私人实体走向公开市场的发展过程中提供重要支持。

Przemek Obloj, CEO of bit.bio, commented: 'By providing reliable human cells for research and safety testing, we’re helping to accelerate drug development and build a world class life sciences business in the UK. Our technology reduces reliance on animal testing while improving the relevance and accuracy of pre-clinical research.

bit.bio首席执行官普热梅克·奥布洛伊评论道：“通过为研究和安全性测试提供可靠的人类细胞，我们正在帮助加速药物开发，并在英国建立一个世界级的生命科学企业。我们的技术减少了对动物试验的依赖，同时提高了临床前研究的相关性和准确性。”

With fresh backing from M&G and our wider investor base, we can accelerate development, from in silico model training through our most established in vitro discovery models and towards safety testing.'.

在M&G和我们更广泛的投资者基础的新支持下，我们可以加速发展，从计算机模拟训练到我们最成熟的体外发现模型，再到安全性测试。

Cornel Chiriac, Investment Director of Crossover, M&G Investments, said: “The investment of patient capital into a fast-growing private UK company, spun out from the University of Cambridge, marks a major vote of confidence in innovation and the future of drug development in the UK. bit.bio’s platform makes cell programming reliable, scalable, and commercially ready in a rapidly evolving field.

Crossover、M&G Investments的投资总监科内尔·基里亚克表示：“将耐心资本投资到一家快速成长的英国私营公司，该公司从剑桥大学分拆出来，这标志着对英国创新和药物开发未来投下了重要的信任票。bit.bio的平台使得在这个快速发展的领域中，细胞编程变得可靠、可扩展，并具备商业化的准备。”

As a long-term investor, M&G is committed to backing the next generation of UK businesses and driving economic progress. With a growing global footprint, bit.bio is a UK success story poised for international growth.”.

作为长期投资者，M&G 致力于支持下一代英国企业并推动经济增长。bit.bio 的全球影响力日益扩大，是一个有望实现国际增长的英国成功案例。”

Lord David Prior concluded: “bit.bio’s technology is world class and the opportunity is now converting that advantage into sustained commercial performance. I look forward to supporting the team as it expands its customer reach and becomes a key partner for pharmaceutical, biotech and research organisations worldwide.”.

大卫·普赖尔勋爵总结道：“bit.bio的技术是世界级的，现在的机会是将这一优势转化为持续的商业表现。我期待着支持团队扩大客户覆盖范围，成为全球制药、生物技术和研究机构的关键合作伙伴。”

https://www.bionity.com/en/news/1187927/bit-bio-secures-50-million-series-c-to-scale-human-cell-programming-technology.html

Start-up wants to decarbonise the wastewater sector - with advanced sensor technology and AI

初创公司希望利用先进的传感器技术和人工智能来实现废水行业的脱碳。

Variolytics Secures Growth Financing Round with Nordic Alpha Partners

Variolytics 获得 Nordic Alpha Partners 的成长融资轮

Read news

读新闻